SGS Clinical Research announces results of FiH studies using novel virus as experimental challenge agent
Strain represents one of the common current circulating strains of influenza of a pandemic origin.
SGS has announced the successful completion of a Phase I clinical trial of a new strain of influenza virus in healthy volunteers. The agent is approved for use as a challenge agent in studies demonstrating the early efficacy of influenza drugs and vaccines in healthy volunteers.
The study, carried out by SGS at their purpose-built human challenge unit, used a GMP-manufactured, non-hemagglutinating, wild-type strain of Influenza A H3N2 in humans at single, ascending titers to determine attack rate (AR), viral area under curve (vAUC) and symptoms following nasal inoculation. Attack rates were defined as two consecutive, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) or quantitative culture (TCID50) positives. The First-in-Human trial demonstrated that the novel challenge agent had high attack rates of up to 100%, no ‘blipping’ at the highest titer and strong symptoms consistent with a non egg-adapted, wild-type influenza virus.
Other highlights of the study, which were presented by Adrian Wildfire, Project Director for Infectious Diseases and the Human Challenge Unit at the recent World Vaccine Congress in Washington DC, included the successful use of the microneutralisation test (MNT) in place of the haemagglutination inhibition assay (HAI) to estimate serosusceptibility prior to challenge. The new assay gave a high degree of predictability regarding infection rates following inoculation. H3N2 (A/Belgium/4217/2015) was shown to cause symptoms consistent with a mild episode of flu in healthy volunteers with no serious adverse events observed during the study or at follow-up.
The SGS challenge agent has lineage from the seasonally epidemic, non-haemagglutinating, H3N2 viruses that arose in the 2010-2011 influenza season and have come to predominate since 2014-2015. This strain represents one of the common current circulating strains of influenza of a pandemic origin. A/Belgium, therefore, offers the potential for testing the H3N2 portion of prospective prophylactic and therapeutic vaccines.
“The outcome of this trial and validation of the virus strain for human challenge trials means future research will not be reliant upon seasonal incidence of influenza, and efficacy of developmental vaccines can be determined directly by measuring multiple clinical endpoints,” commented Mr. Wildfire. “This approach is safer for study participants, and informed go/no go decisions can be made sooner to avoid potentially costly late phase failures.”
Challenge agent manufacture has been undertaken by SGS in strict accordance with Good Manufacturing Practice to ensure that regulatory guidelines in both the US and EU (FDA and EMA) are met
.Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance